The consistent professionalism of management shows
Post# of 72451
Posted On: 02/24/2013 3:29:08 PM
The consistent professionalism of management shows a high level of respect for shareholders, and continues with this latest release (Jeff, your "ATL" acronym-- always trust Leo-- seems right-on).
This PR, which will hit the news wires tomorrow morning, exudes confidence without fluff, while bringing us up to date, explaining the "quiet period" and setting time frames going forward. Thanks to TP for fleshing out the relevant points of this PR, for which I could only give a brief outline elsewhere on Friday.
I doubt that Dr. Menon would set a time frame (and thus expectations) for the first P21 biomarker data if the company did not plan on disclosing this data to the extent they are allowed.
Which bring up an interesting question: if the initial P21 data is positive (and by implication P53 is activated), would this not be considered a "material event" and under sec regulations require disclosure within days? At the same time, there is a strict protocol to follow at DF and BI, which may run counter to such disclosure. Which set of "rules" must the company follow?
Regarding SP: I see a strong 2 handle by end of this week, unless the broad market (and/or biotech sector as a whole) goes way down.
I recently took the liberty of reviewing the first 500 posts since the hub board's inception (long plane ride)and found it very instructive to see who has been around pre-Evans and pre-Formatech. I also found the distinction between "family of investors" vs. "horde of traders" to be edifying, as these phenomena happen with all "story stocks."
Like in the old Western movies, the thundering hoofs of those who crave volatility can be heard faintly in the distance, as dust begins to billow on the horizon.
GL
This PR, which will hit the news wires tomorrow morning, exudes confidence without fluff, while bringing us up to date, explaining the "quiet period" and setting time frames going forward. Thanks to TP for fleshing out the relevant points of this PR, for which I could only give a brief outline elsewhere on Friday.
I doubt that Dr. Menon would set a time frame (and thus expectations) for the first P21 biomarker data if the company did not plan on disclosing this data to the extent they are allowed.
Which bring up an interesting question: if the initial P21 data is positive (and by implication P53 is activated), would this not be considered a "material event" and under sec regulations require disclosure within days? At the same time, there is a strict protocol to follow at DF and BI, which may run counter to such disclosure. Which set of "rules" must the company follow?
Regarding SP: I see a strong 2 handle by end of this week, unless the broad market (and/or biotech sector as a whole) goes way down.
I recently took the liberty of reviewing the first 500 posts since the hub board's inception (long plane ride)and found it very instructive to see who has been around pre-Evans and pre-Formatech. I also found the distinction between "family of investors" vs. "horde of traders" to be edifying, as these phenomena happen with all "story stocks."
Like in the old Western movies, the thundering hoofs of those who crave volatility can be heard faintly in the distance, as dust begins to billow on the horizon.
GL
(0)
(0)